Comments on National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)

Chin J Cancer Res. 2022 Oct 30;34(5):447-450. doi: 10.21147/j.issn.1000-9604.2022.05.02.

Hao Wang¹, Jian Wang², Xiang Wang³, Yiming Zhu⁴, Yuqing Sun^{5

6}, Xin Zhang^{5

6}, Xiaorong Hou⁷, Kun Zheng^{5

6}, Shaoyan Liu², Yansong Lin^{5

6}

¹ Department of Clinical Oncology, Qingdao Municipal Hospital, Qingdao University, Qingdao 266012, China.
² Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
³ Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
⁴ Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
⁵ Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
⁶ Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing 100730, China.
⁷ Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

No abstract available